Fig. 1: Increasing mitochondrial priming enhances NSCLC cell lines sensitivity to conventional chemotherapy.
From: Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
Cell lines (A549, H522, H1975, H3255 and PC9) were exposed to various targeted agents and mitochondrial priming was assessed. In parallel cells were treated to a dose response of chemotherapy ± targeted agent and chemosensitivity was assessed. A Schematic showing the workflow for measuring drug-induced priming using DBP and chemosensitivity using cell viability assay. Created with BioRender.com. B Top heat map shows normalized mitochondrial priming (BIM EC50) for individual targeted agents at indicated concentrations or DMSO-control. Bottom heat map shows normalized chemosensitivity to etoposide or docetaxel plus targeted agent or DMSO-control. C These graphs show the correlation between mitochondrial priming (BIM EC50) Vs. chemosensitivity (etoposide EC50 or docetaxel EC50) for each cell line for various drugs at specific concentrations or DMSO-control (either BIM, etoposide or docetaxel only). Data represents the mean BIM EC50, etoposide EC50 or docetaxel EC50 of three independent experiments ± standard deviation.
